Voglibose

ALIMENTARY TRACT AND METABOLISM

Key facts

Voglibose is a drug catalogued in DrugCentral. It was first approved by the PMDA in 1994. DrugCentral lists 5 molecular targets, including Si, GAA and Gaa. Recorded indications include Diabetes mellitus type 2 and Glucosylceramide beta-glucosidase deficiency.

• Molecular targets: Si, GAA, Gaa and MGAM (5 listed in DrugCentral).
• Indications: Diabetes mellitus type 2 and Glucosylceramide beta-glucosidase deficiency.
• ATC code: A10BF03 (Alpha glucosidase inhibitors).
• Molecular formula: C10H21NO7; molecular weight 267.28 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Diabetes mellitus type 2
• Glucosylceramide beta-glucosidase deficiency

Contraindications (4)

• Breastfeeding (mother)
• Impaired renal function disorder
• Peripheral nerve disease
• Pregnancy, function

Mechanism & targets

Molecular targets (5)

Target	Gene	Action	Activity
Sucrase-isomaltase, intestinal	Si	unknown	IC50 7.15
Lysosomal alpha-glucosidase	GAA	inhibitor	IC50 7.15
Lysosomal alpha-glucosidase	Gaa	unknown	IC50 6.96
Maltase-glucoamylase, intestinal	MGAM	unknown	IC50 5.89
Glycogen debranching enzyme	AGL	unknown	IC50 4.15

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1994-08-20	PMDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
A10BF03	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Alpha glucosidase inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hypoglycaemia	229.8
Cerebral infarction	182.7
Renal impairment	118.9
Pneumatosis intestinalis	118.7
Interstitial lung disease	97.8
Hepatic function abnormal	83.9
Hypoglycaemic coma	80.8
Glycosylated haemoglobin increased	76.5
Pemphigoid	74.4
Lactic acidosis	66.5
Diabetes mellitus inadequate control	64.6
Platelet count decreased	50.1

Chemical structure

• Molecular formula: C₁₀H₂₁NO₇
• Molecular weight: 267.28 g/mol
• CAS number: —
• InChIKey: FZNCGRZWXLXZSZ-CIQUZCHMSA-N
• PubChem CID: 444020

OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Voglibose used for?

DrugCentral lists the following indications for Voglibose: Diabetes mellitus type 2 and Glucosylceramide beta-glucosidase deficiency.

How does Voglibose work?

Its molecular targets in DrugCentral include Si, GAA (inhibitor), Gaa and MGAM.

When was Voglibose first approved?

Voglibose was first approved by the PMDA in 1994.

What is the chemical formula of Voglibose?

Voglibose has the molecular formula C10H21NO7 and a molecular weight of 267.28 g/mol.

Sources

• DrugCentral drug card 2845 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL476960 — compound record and bioactivity
• PubChem CID 444020 — chemical identifiers
• DrugBank DB04878 — drug record
• FDA UNII S77P977AG8 — substance identity
• UniProt P10253 (GAA) — target protein
• UniProt O43451 (MGAM) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.